Decision on rights issue subject to approval at Extraordinary General Meeting
Hørsholm, Denmark, 30 november 2017 – Oncology Venture Sweden AB (“Oncology Venture”) hereby announces that the board has decided to – subject to approval on Extraordinary General Meeting – conduct a rights issue of up to 2 745 143 shares at an issue price of 16,30 SEK per share. Fully subscribed rights issue provides Oncology Venture approximately 44,7 million SEK before issuing costs. The general public are also invited to subscribe for shares in the rights issue. Beforehand, Oncology Venture has agreed on subscription commitments amounting to approximately 15,8 million SEK and guarantee